SNAI2 and breast carcinoma: The METABRIC dataset24,25 was queried to evaluate the prognostic value of alterations in SMAD4 and SNAI2. Using gene expression data from 2509 breast cancer patients followed for ~35 years, SMAD4 or SNAI2 mRNA expression alterations occur in 8 and 13% of patients, respectively.